(3Z)-2-amino-4-(1H-indol-5-yl)buta-1,3-diene-1,1,3-tricarbonitrile

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (3Z)-2-amino-4-(1H-indol-5-yl)buta-1,3-diene-1,1,3-tricarbonitrile
• 化学式: C₁₅H₉N₅
• 分子量: 259.27
• InChiKey: CMMDWEJTQUTCKG-WUXMJOGZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  113
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX
  申请人：Deng Huayun

  公开号：US20120022116A1

  公开（公告）日：2012-01-26

  Disclosed are compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically related to GPR35, and/or GPR35-hERG signaling complex. For example, disclosed are compounds for preventing and/or treating diseases which are pathophysiologically related to GPR35 in a subject. The compounds having a formula (I), (II) or (III):

  揭示了与GPR35及/或GPR35-hERG信号复合物在病理生理上相关的疾病的预防和/或治疗的组合物和方法。例如，揭示了用于预防和/或治疗与GPR35在受试者中病理生理相关的疾病的化合物。这些化合物具有以下公式(I)、(II)或(III)：
• Cermide Kinase Modulation
  申请人：Bornancin Frederic

  公开号：US20090170914A1

  公开（公告）日：2009-07-02

  A compound of formula (I) wherein R 1 is a straight chain, branched or cyclic aliphatic, aromatic or heterocyclyl group comprising at least 8 carbon atoms, e.g. 8 to 22, R 2 is a straight chain, branched or cyclic aliphatic, aromatic or heterocyclic group comprising from 1 to 12 carbon atoms, and ring A is heterocycyl, fused with the phenyl ring to which ring A is attached comprising 5 or 6 ring members, and 1 to 4 heteroatoms selected from N, S, O; wherein certain compounds are excluded by proviso and the use of such compounds without proviso as pharmaceuticals in disorders which are mediated by ceramide kinase.

  式（I）的化合物中，其中R1是直链、支链或环状的脂肪族、芳香族或杂环基团，含有至少8个碳原子，例如8到22个碳原子；R2是直链、支链或环状的脂肪族、芳香族或杂环基团，含有1到12个碳原子；环A是杂环基团，与环A连接的苯环融合，包括5个或6个环成员和1到4个N、S、O中选择的杂原子；其中通过约定排除了某些化合物，并且在没有约定的情况下使用这些化合物作为通过神经酰胺激酶介导的疾病的药物。
• [EN] NOVEL COMPOUNDS FOR USE IN TREATING OR PREVENTING CANCEROUS DISEASES<br/>[FR] NOUVEAUX COMPOSÉS UTILISABLES DANS LE TRAITEMENT OU LA PRÉVENTION DE MALADIES CANCÉREUSES
  申请人：BIOMEDICAL RES FOUND OF THE ACAD OF ATHENS

  公开号：WO2017005919A1

  公开（公告）日：2017-01-12

  The invention relates to new compounds of formula (I) that are useful in medicine, specifically in treating or preventing cancerous diseases in a mammal, to pharmaceutical compositions comprising such compounds, optionally together with other pharmaceutically active compounds, or to pharmaceutical formulations comprising such compounds or pharmaceutical compositions. The invention further relates to methods of making these compounds.

  本发明涉及公式（I）的新化合物，该化合物在医学上具有用途，特别是在哺乳动物中治疗或预防癌症性疾病，以及包含这些化合物的药物组合物，可选地与其他药物活性化合物一起，或包含这些化合物或药物组合物的药物制剂。本发明还涉及制备这些化合物的方法。
• Cholanic Acid Amides
  申请人：Schreiner Erwin Paul

  公开号：US20090258847A1

  公开（公告）日：2009-10-15

  4-(3-hydroxy-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-17-yl)-pentanoic acid amides wherein the nitrogen of the amide group is substituted by a sulfonylaminocarbonyl-(C 1-4 )-alkyl group; and the use of such compounds as pharmaceuticals.

  4-(3-羟基-10,13-二甲基-十六烷基环戊-α-苯并芘-17-基)-戊酸酰胺，其中酰胺基的氮原子被磺酰氨基羰基-(C1-4)-烷基取代；以及将这些化合物用作药物的用途。
• Inhibitors of Ccr9 Activity
  申请人：Carballido Herrera Jose M.

  公开号：US20080269312A1

  公开（公告）日：2008-10-30

  N-(benzenesulphonyl)-2,3-dihydro-1H-indols, wherein the indol is substituted by cyano, carboxy or alkylcarbonyloxy and their use as therapeutical agents.

  N-(苯磺酰基)-2,3-二氢-1H-吲哚，其中吲哚被氰基，羧基或烷基羧酸酯取代，并且它们作为治疗剂使用。